Increased antibody levels to stage-specific Epstein–Barr virus antigens in systemic autoimmune diseases reveal a common pathology

References

• Draborg AH, Duus K, Houen G. Epstein–Barr virus in systemic autoimmune diseases. Clin Dev Immunol. 2013;2013:535738.
   PubMedGoogle Scholar
• Sestak AL, Fürnrohr BG, Harley JB, et al. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis. 2011;70 Suppl 1:i37–i43.
   PubMed Web of Science ®Google Scholar
• Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, et al. HLA and Sjögren’s syndrome susceptibility. A metaanalysis of worldwide studies. Autoimmun Rev. 2012;11:281–287.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Davis III JM, Crowson CS, et al. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12:379–385.
   PubMedGoogle Scholar
• James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein–Barr virus exposure. Arthritis Rheum. 2001;44:1122–1126.
   PubMed Web of Science ®Google Scholar
• Wu H, Kapoor P, Frappier L. Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein–Barr nuclear antigen 1. J Virol. 2002;76:2480–2490.
   PubMed Web of Science ®Google Scholar
• Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein–Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity. 2008;41:298–328.
   PubMed Web of Science ®Google Scholar
• Frappier L. The Epstein–Barr virus EBNA1 protein. Scientifica (Cairo). 2012;2012:438204.
   PubMedGoogle Scholar
• Tsurumi T, Kobayashi A, Tamai K, et al. Functional expression and characterization of the Epstein–Barr virus DNA polymerase catalytic subunit. J Virol. 1993;67:4651–4658.
   PubMed Web of Science ®Google Scholar
• Hammerschmidt W, Sugden B. Replication of Epstein–Barr viral DNA. Cold Spring Harb Perspect Biol. 2013;5:a013029.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Middeldorp J, Madjar JJ, et al. A major DNA binding protein encoded by BALF2 open reading frame of Epstein–Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D, and DNA polymerase. Virology. 1997;22:285–295.
   Web of Science ®Google Scholar
• Narita Y, Murata T, Ryo A, et al. Pin1 interacts with the Epstein–Barr virus DNA polymerase catalytic subunit and regulates viral DNA replication. J Virol. 2013;87:2120.
   PubMed Web of Science ®Google Scholar
• Grunsven W, Heerde E, Haard H, et al. Gene mapping and expression of two immunodominant Epstein–Barr virus capsid proteins. J Virol. 1993;67:3908–3916.
   PubMed Web of Science ®Google Scholar
• Hinderer W, Lang D, Rothe M, et al. Serodiagnosis of Epstein–Barr virus infection by using recombinant viral capsid antigen fragments and autologous gene fusion. J Clin Microbiol. 1999;37:3239–3244.
   PubMed Web of Science ®Google Scholar
• Reischl U, Gerdes C, Motz M, et al. Expression and purification of an Epstein–Barr virus encoded 23-kDa protein and characterization of its immunological properties. J Virol Methods. 1996;57:71–85.
   PubMed Web of Science ®Google Scholar
• Tarodi B, Subramanian T, Chinnadurai G. Epstein–Barr virus BHRF1 protein protects against cell death induced by DNA-damaging agents and heterologous viral infection. Virology. 1994;201:404–407.
   PubMed Web of Science ®Google Scholar
• Young KA, Herbert AP, Barlow PN, et al. Molecular basis of the interaction between complement receptor Type 2 (CR2/CD21) and Epstein–Barr virus glycoprotein gp350. J Virol. 2008;82:11217–11227.
   PubMed Web of Science ®Google Scholar
• Spear PG, Longnecker R. Herpesvirus entry: an update. J Virol. 2003;77:10179–10185.
   PubMed Web of Science ®Google Scholar
• Kirschner AN, Sorem J, Longnecker R, et al. Structure of Epstein–Barr virus glycoprotein 42 suggests a mechanism for triggering receptor-activated virus entry. Structure. 2009;13:223–233.
   Web of Science ®Google Scholar
• Trier N, Izarzugaza J, Chailyan A, et al. Human MHC-II with shared epitope motifs are optimal Epstein–Barr virus glycoprotein 42 ligands-relation to rheumatoid arthritis. Int J Mol Sci. 2018;21:19.
   Google Scholar
• Chen J, Zhang X, Jardetzky TS, et al. The Epstein–Barr Virus (EBV) glycoprotein B cytoplasmic C-terminal tail domain regulates the energy requirement for EBV-induced membrane fusion. J Virol. 2014;88:11686–11695.
   PubMed Web of Science ®Google Scholar
• Henle W, Henle G, Andersson J, et al. Antibody responses to Epstein–Barr virus determined nuclear antigen (EBNA)-1 and EBNA2 in acute and chronic Epstein–Barr virus infection. Proc Natl Acad Sci U S A. 1987;84:570–574.
   PubMed Web of Science ®Google Scholar
• Schmitz H, Volz D, Krainick-Riechert C, et al. Acute Epstein–Barr virus infections in children. Med Microbiol Immunol. 1972;158:58.
   PubMed Web of Science ®Google Scholar
• Nikoskelainen J, Neel EU, Stevens DA. Epstein–Barr virus-specific serum immunoglobulin A as an acute-phase antibody in infectious mononucleosis. J Clin Microbiol. 1979;10:75–79.
   PubMed Web of Science ®Google Scholar
• Evans AS, Niederman JC, Cenabre LC, et al. A prospective evaluation of heterophile and Epstein–Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: specificity and sensitivity of the tests and persistence of antibody. J Infect Dis. 1975;132:546–554.
   PubMed Web of Science ®Google Scholar
• Fleisher G, Henle W, Henle G, et al. Primary infection with Epstein–Barr virus in infants in the United States: clinical and serologic observations. J Infect Dis. 1979;139:553–558.
   PubMed Web of Science ®Google Scholar
• Lamy ME, Favart AM, Cornu C, et al. Study of Epstein–Barr virus (EBV) antibodies: IgG and IgM anti-VCA, IgG anti-EA and Ig anti-EBNA obtained with an original microtiter technique: serological criterions of primary and recurrent EBV infections and follow-up of infectious mononucleosis-seroepidemiology of EBV in Belgium based on 5178 sera from patients. Acta Clin Bel. 1982;37:281–298.
   PubMed Web of Science ®Google Scholar
• Färber I, Hinderer W, Rothe M, et al. Serological diagnosis of Epstein–Barr virus infection by novel ELISAs based on recombinant capsid antigens p23 and p18. J Med Virol. 2001;63:271–276.
   PubMed Web of Science ®Google Scholar
• Gärtner BC, Hess RD, Bandt D, et al. Evaluation of four commercially available Epstein–Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin Diag Lab. Immunol. 2003;10:78–82.
   Web of Science ®Google Scholar
• Hess RD. Routine Epstein–Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol. 2004;42:3381–3387.
   PubMed Web of Science ®Google Scholar
• Sternbæk L, Draborg AH, Nielsen CT, et al. Efficient evaluation of humoral immune responses by the use of serum pools. J Immunol Methods. 2017;443:1–8.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthitis Rheum. 2010;62:2569–2581.
   PubMed Web of Science ®Google Scholar
• Shiboski SC, Shiboski CH, Criswell LA, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res. 2012;64:475–487.
   PubMed Web of Science ®Google Scholar
• Hoogen F, Khanna D, Fransen J, et al. Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative. Arthritis Rheum. 2013;65:2737–2747.
   PubMed Web of Science ®Google Scholar
• Draborg AH, Jørgensen JM, Müller H, et al. Epstein–Barr virus early antigen diffuse (EBV-EA/D)-directed immunoglobulin A antibodies in systemic lupus erythematosus patients. Scand J Rheumatol. 2012;41:280–289.
   PubMed Web of Science ®Google Scholar
• Murphy K, Janemay CA, Travers P, et al. Janeway’s immuno biology. 8th ed. New York: Garland Science; 2012.
   Google Scholar
• Westergaard MW, Draborg AH, Troelsen L, et al. Isotypes of Epstein–Barr virus antibodies in Rheumatois arthritis: associated with rheumatoid factors and citrulline-dependent antibodies. J Biomed Biotech. 2015;2015:1–9.
   Google Scholar
• Huggins ML, Todd I, Powell RJ. Reactivation of Epstein–Barr virus in patients with systemic lupus erythematosus. Rheumatol Int. 2005;25:183–187.
   PubMed Web of Science ®Google Scholar
• Tsurumi T, Kobayashi A, Tamai K, et al. Epstein–Barr virus single-stranded DNA-binding protein: purification, characterization, and action on DNA synthesis by the viral DNA polymerase. Virology. 1996;15:352–364.
   Web of Science ®Google Scholar
• Jonsson R, Vogelsang P, Volchenkos R, et al. The complexity of Sjögren’s syndrome: novel aspects on pathogenesis. Immunol Lett. 2011;30:1–9.
   Web of Science ®Google Scholar
• Ciechomska M, van Laar J, O'Reilly S. Current frontiers in systemic sclerosis pathogenesis. Exp Dermatol. 2015;24:401–406.
   PubMed Web of Science ®Google Scholar
• Gordon C, Li CK, Isenberg DA. Systemic lupus erythematosus. Medicine. 2010;38:73–80.
   Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–939.
   PubMed Web of Science ®Google Scholar
• Smith PP, Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev. 2010;10:43–45.
   PubMed Web of Science ®Google Scholar
• Fattal I, Shental N, Molad Y, et al. Epstein–Barr virus antibodies mark systemic lupus erythematosus and scleroderma patients negative for anti-DNA. Immunology. 2014;141:276–285.
   PubMed Web of Science ®Google Scholar
• Pasoto SG, Natalino RR, Chakkour HP, et al. EBV reactivation serological profile in primary Sjögren’s syndrome: an underlying trigger of active articular involvement? Rheumatol Int. 2013;33:1149–1157.
   PubMed Web of Science ®Google Scholar
• Tosato G, Steinberg AD, Yarchoan R, et al. Abnormally elevated frequency of Epstein–Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest. 1984;73:1789–1795.
   PubMed Web of Science ®Google Scholar
• Neuhierl B, Feederle R, Hammerschmidt W, et al. Glycoprotein gp110 of Epstein–Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci U S A. 2002;99:15036–15041.
   PubMed Web of Science ®Google Scholar
• Francois A, Chatelus E, Wachsmann D, et al. B lymphocytes and B-cells activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther. 2013;15:R168.
   PubMed Web of Science ®Google Scholar
• Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein–Barr virus. Nat Med. 2002;8:594–599.
   PubMed Web of Science ®Google Scholar
• Bettencourt A, Carvalho C, Leal B, et al. The protective role of HLA-DRB1(∗)13 in autoimmune diseases. J Immunol Res. 2015;2015:948723.
   PubMed Web of Science ®Google Scholar